Jaguar animal health sponsors october 26th episode of dvm360 live! to drive awareness of canalevia-ca1 and participation in jaguar's take c.h.a.r.g.e.

Canalevia®-ca1, which received conditional approval from the fda on december 21, 2021 , is the first and only treatment for chemotherapy-induced diarrhea (cid) in dogs to receive any type of approval from the fda san francisco, ca / accesswire / october 27, 2022 / jaguar health, inc. (nasdaq:jagx), under its jaguar animal health tradename for the veterinary market, today announced that the company sponsored the october 26, 2022 episode of dvm360 live! ™, a web-based, magazine-style talk show for veterinary professionals hosted by adam christman, dvm, mba, to drive awareness of the company's canalevia-ca1 drug product and encourage veterinary clinics to contribute canine cancer records to the take c.h.a.r.g.e.
JAGX Ratings Summary
JAGX Quant Ranking